{"classes":[{"categories":[{"measurements":[{"comment":"NA indicated that the upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"15.9","upperLimit":"NA","value":"18.0"},{"groupId":"OG001","lowerLimit":"6.9","upperLimit":"15.2","value":"9.9"}]}],"title":"Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.9","upperLimit":"14.6","value":"10.3"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"6.9","value":"5.5"}]}],"title":"Role Functioning"},{"categories":[{"measurements":[{"comment":"NA indicated that the upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"18.6","upperLimit":"NA","value":"28.2"},{"comment":"NA indicated that the upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"12.4","upperLimit":"NA","value":"17.3"}]}],"title":"Emotional Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"16.6","value":"11.8"},{"groupId":"OG001","lowerLimit":"7.8","upperLimit":"13.8","value":"9.9"}]}],"title":"Cognitive Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.6","upperLimit":"16.3","value":"11.7"},{"groupId":"OG001","lowerLimit":"6.2","upperLimit":"10.4","value":"7.7"}]}],"title":"Social Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.4","upperLimit":"7.7","value":"4.3"},{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"4.2","value":"2.9"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"comment":"NA indicated that the upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"17.2","upperLimit":"NA","value":"22.0"},{"groupId":"OG001","lowerLimit":"4.8","upperLimit":"9.6","value":"6.3"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"5.6","value":"3.5"},{"groupId":"OG001","lowerLimit":"7.7","upperLimit":"21.5","value":"13.8"}]}],"title":"Nausea/Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"14.7","value":"11.3"},{"groupId":"OG001","lowerLimit":"7.7","upperLimit":"13.3","value":"10.5"}]}],"title":"Global Health Status/QoL"},{"categories":[{"measurements":[{"comment":"NA indicated that the upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"19.3","upperLimit":"NA","value":"20.0"},{"comment":"NA indicated that the upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"13.1","upperLimit":"NA","value":"20.8"}]}],"title":"Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.0","upperLimit":"11.7","value":"8.3"},{"groupId":"OG001","lowerLimit":"9.6","upperLimit":"16.1","value":"13.8"}]}],"title":"Loss of Appetite"},{"categories":[{"measurements":[{"comment":"NA indicated that the median and upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"17.3","upperLimit":"NA","value":"NA"},{"comment":"NA indicated that the upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"12.4","upperLimit":"NA","value":"15.2"}]}],"title":"Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.5","upperLimit":"12.5","value":"9.2"},{"comment":"NA indicated that the upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"15.9","upperLimit":"NA","value":"22.0"}]}],"title":"Constipation"},{"categories":[{"measurements":[{"comment":"NA indicated that the upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"17.2","upperLimit":"NA","value":"29.0"},{"groupId":"OG001","lowerLimit":"13.9","upperLimit":"23.4","value":"16.5"}]}],"title":"Diarrhea"}],"denoms":[{"counts":[{"groupId":"OG000","value":"436"},{"groupId":"OG001","value":"430"}],"units":"Participants"}],"description":"Time to deterioration was defined as the time from randomization until the date of the first clinically meaningful deterioration that was confirmed at next available assessment, at least 14 days apart, regardless of whether the participant withdrew from study treatment or receives another anti-cancer therapy prior to deterioration.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received T-DXd 5.4 mg/kg via IV infusion every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG000","title":"T-DXd"},{"description":"Participants received Investigator's choice single-agent chemotherapy (capecitabine 1000 or 1250 mg/m\\^2 orally twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles, paclitaxel 80 mg/m\\^2 via IV infusion qw in 3-week cycles or nab-paclitaxel 100 mg/m\\^2 via IV infusion qw for 3 weeks followed by 1-week rest period in 4-week cycles) until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization until date of first symptom deterioration that is confirmed, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)","title":"Time to Deterioration in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Scale Score","type":"SECONDARY","unitOfMeasure":"months"}